Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ALEC 
Alector Inc (ALEC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/12/2025: ALEC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.51
1 Year Target Price $4.51
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.44% | Avg. Invested days 16 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 225.70M USD | Price to earnings Ratio - | 1Y Target Price 4.51 |
Price to earnings Ratio - | 1Y Target Price 4.51 | ||
Volume (30-day avg) 9 | Beta 0.86 | 52 Weeks Range 0.87 - 6.37 | Updated Date 08/12/2025 |
52 Weeks Range 0.87 - 6.37 | Updated Date 08/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-01 | When - | Estimate -0.47 | Actual -0.3 |
Profitability
Profit Margin -142.1% | Operating Margin (TTM) -433.55% |
Management Effectiveness
Return on Assets (TTM) -17.84% | Return on Equity (TTM) -103.99% |
Valuation
Trailing PE - | Forward PE 526.32 | Enterprise Value -50190493 | Price to Sales(TTM) 2.78 |
Enterprise Value -50190493 | Price to Sales(TTM) 2.78 | ||
Enterprise Value to Revenue 2.38 | Enterprise Value to EBITDA -8.4 | Shares Outstanding 101212000 | Shares Floating 74691662 |
Shares Outstanding 101212000 | Shares Floating 74691662 | ||
Percent Insiders 10.48 | Percent Institutions 80.92 |
Upturn AI SWOT
Alector Inc
Company Overview
History and Background
Alector Inc. was founded in 2013 and is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for treating neurodegenerative diseases by harnessing the power of the immune system. They focus on modulating microglia, the brain's immune cells, to combat diseases like Alzheimer's and Frontotemporal Dementia (FTD). Alector has established partnerships with major pharmaceutical companies to advance their pipeline.
Core Business Areas
- Immuno-Neurology Therapeutics: Development of monoclonal antibodies and small molecules targeting immune system regulation in the brain to treat neurodegenerative diseases.
- Microglia Modulation: Focuses on modulating the function of microglia cells to clear toxic proteins and reduce inflammation in the brain.
Leadership and Structure
Alector is led by a board of directors and an executive team. Key figures include the CEO, Chief Scientific Officer, and Chief Medical Officer. The company has a structure typical of biotechnology firms, with departments focused on research and development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- AL001: A monoclonal antibody targeting SIGLEC3 (CD33) for the treatment of Alzheimer's disease. It aims to enhance the brain's ability to clear amyloid plaques. Currently in clinical trials. Competitors include companies developing anti-amyloid therapies like Biogen (LEQEMBI) and Eisai.
- AL101: A monoclonal antibody targeting SORT1 for the treatment of Frontotemporal Dementia (FTD) in GRN mutation carriers. Currently in clinical trials. Competitors are limited due to the specific genetic target, but other companies are developing gene therapies for FTD.
- AL002: A monoclonal antibody targeting TREM2 to treat Alzheimer's. Alector partnered with AbbVie to develop and commercialize AL002. Competing drugs also target TREM2 from companies such as Denali Therapeutics.
Market Dynamics
Industry Overview
The neurodegenerative disease market is large and growing due to an aging population. Significant unmet medical needs exist for effective treatments for diseases like Alzheimer's and FTD. The industry is characterized by high research and development costs and a high failure rate for clinical trials.
Positioning
Alector is a pioneer in immuno-neurology, offering a novel approach to treating neurodegenerative diseases that differentiates it from companies focused on traditional amyloid or tau pathways. Their focus on microglia modulation provides a unique competitive advantage.
Total Addressable Market (TAM)
The global Alzheimer's disease therapeutics market is projected to reach hundreds of billions of dollars. The FTD market is smaller but still significant. Alector is positioned to capture a substantial share of these markets if their clinical trials are successful.
Upturn SWOT Analysis
Strengths
- Novel immuno-neurology approach
- Strong partnerships with major pharmaceutical companies
- Pipeline of promising clinical-stage assets
- Experienced management team
Weaknesses
- High R&D costs and reliance on clinical trial success
- Dependence on partnerships for funding and commercialization
- Limited revenue stream
Opportunities
- Potential to address significant unmet medical needs in neurodegenerative diseases
- Expansion of pipeline through internal research and acquisitions
- Growing awareness and acceptance of immuno-neurology as a therapeutic approach
- Partnerships for future drug development
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- BIIB
- DNL
- SNY
Competitive Landscape
Alector's immuno-neurology approach provides a unique competitive advantage. However, they face competition from larger, more established pharmaceutical companies with greater resources and established pipelines in neurodegenerative diseases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by pipeline advancement and partnership formation.
Future Projections: Future growth is dependent on the success of clinical trials and the expansion of their pipeline. Analyst estimates vary depending on the perceived probability of success for their key assets.
Recent Initiatives: Recent initiatives include advancing clinical trials for AL001 and AL101 and continuing their partnership with AbbVie.
Summary
Alector is a pioneering biotech company with a novel approach to treating neurodegenerative diseases. Their strengths lie in their unique scientific approach and established partnerships; however, the high risk of clinical trial failures and reliance on external funding are weaknesses. Success hinges on the outcome of ongoing clinical trials and continued financial support from partners. The company shows promise but requires investors to carefully monitor the data as it progresses.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Company Website
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The biotechnology industry is inherently risky, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alector Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-02-07 | Co-Founder, CEO & Director Dr. Arnon Rosenthal Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 163 | Website https://www.alector.com |
Full time employees 163 | Website https://www.alector.com | ||
Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN) which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency and is in Phase 3 clinical trial. It also develops AL101/GSK4527226 that is in Phase 2 clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In addition, the company's preclinical and research pipeline products include ADP037-ABC, a proprietary anti-amyloid beta (Aß) antibody paired with proprietary ABC for the treatment of AD; ADP050-ABC, a GCase replacement therapy paired with proprietary ABC for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia; ADP056, a Reelin modulator designed to block tau pathology and promote synaptic function in AD; and ADP063-ABC and ADP064-ABC that are therapeutic candidates paired with proprietary ABC that target tau pathology in AD through distinct approaches. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.